Drug intelligence / Profile preview

LBS-101

Development stage: Preclinical
Lead developer: Logic Biosciences
Modality: Small Molecules
Administration: Topical

Overview

LBS-101 is a long-acting topical formulation of bupivacaine, a local anesthetic, being developed by Logic Biosciences. It is intended for the treatment of oral pain resulting from oral mucositis, a common and debilitating side effect of chemotherapy or radiation therapy for cancer. The drug's formulation aims to provide prolonged pain relief in the oral cavity.

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on LBS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBS-101.

Explore the full profile